Research
Hormonal
The macrovascular benefits of GLP-1 receptor agonists should be prioritized over potential microvascular progression of DR.
Healthcare providers should weigh the cardiovascular benefits of GLP-1 receptor agonists against the risks of worsening DR.
StrongSupportsmedium confidence
Overall, the macrovascular reduction of cardiovascular and stroke risks from GLP-1 receptor agonists should be prioritized over the potential microvascular progression of DR.
Why this rating
Based on the context provided in the abstract.
Source
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy
Anindya Samanta et al. · International Ophthalmology Clinics · 2024
reviewCited 6×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →